SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-038957
Filing Date
2023-11-01
Accepted
2023-11-01 09:00:37
Documents
59
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1233636
2 ex31-1.htm EX-31.1 20773
3 ex31-2.htm EX-31.2 20133
4 ex32-1.htm EX-32.1 6311
5 ex32-2.htm EX-32.2 5898
  Complete submission text file 0001493152-23-038957.txt   5754400

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE gtbp-20230930.xsd EX-101.SCH 41837
7 XBRL CALCULATION FILE gtbp-20230930_cal.xml EX-101.CAL 39381
8 XBRL DEFINITION FILE gtbp-20230930_def.xml EX-101.DEF 180486
9 XBRL LABEL FILE gtbp-20230930_lab.xml EX-101.LAB 338337
10 XBRL PRESENTATION FILE gtbp-20230930_pre.xml EX-101.PRE 272378
53 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 930677
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40023 | Film No.: 231366743
SIC: 2834 Pharmaceutical Preparations